US Patent

US7893074 — 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

Composition of Matter · Assigned to IRM LLC · Expires 2026-04-25 · 0y expired

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel pyrimidine derivatives of formula I and processes for their production, use as pharmaceuticals, and in pharmaceutical compositions.

USPTO Abstract

Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Drugs covered by this patent

Patent Metadata

Patent number
US7893074
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-04-25
Drug substance claim
Yes
Drug product claim
Yes
Assignee
IRM LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.